Gilead, Allergan, Novo and Valeant chiefs make the list of world's top 10

Gilead CEO John Martin

Pharma CEOs are doing a pretty good job at the helm--at least where the Harvard Business Review is concerned. Four of them--Gilead Sciences' ($GILD) John Martin, Allergan's ($AGN) David Pyott, Novo Nordisk's ($NVO) Lars Rebien Sorensen and Valeant Pharmaceuticals' ($VRX) J. Michael Pearson--made the publication's top 10, ranked by their market cap growth and shareholder returns. More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.